Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.

Thumbnail
View/Open
Accepted version (529.3Kb)
Date
2016-07
ICR Author
van der Graaf, Wilhelmina
Judson, Ian
Author
Ray-Coquard, I
Rizzo, E
Blay, JY
Casali, P
Judson, I
Hansen, AK
Lindner, LH
Dei Tos, AP
Gelderblom, H
Marreaud, S
Litière, S
Rutkowski, P
Hohenberger, P
Gronchi, A
van der Graaf, WT
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Objective UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical behavior UtS.Methods Information on 269 patients with advanced or metastatic first line UtS treated by chemotherapy was available in a database containing information on 3270 patients with advanced soft tissue sarcomas (STS) entered in EORTC-STBSG clinical trials between 1977 and 2010. The chemotherapy was aggregated in 4 categories: anthracyclines alone, ifosfamide alone, the combination of doxorubicin and ifosfamide, and CYVADIC.Results Among the 269 UtS pts, there were 231 deaths (median OS 10.4months, 95% CI: 9.1-11.9) and 257 progressions and/or deaths (median PFS 4.1months, 95% CI: 3.5-4.9). Multivariate analyses reported PS (p<0.001) only to be a statistically significant prognostic factor for OS in UtS; for PFS, LMS histology (p=0.025) is associated with a better outcome. There was no relationship between the 4 groups of chemotherapy regimens and impact on clinical outcomes. Histological subtype was significantly correlated with response to chemotherapy (RR: LMS 19% vs other 33%, p=0.026). Ifosfamide single agent yielded only 5% of RR.Conclusions Clearly, UtS are very aggressive neoplasms with poor outcome when treated with chemotherapy consisting of anthracyclines with or without ifosfamide or cyclophosphamide. New strategies are urgently needed.
URI
https://repository.icr.ac.uk/handle/internal/325
DOI
https://doi.org/10.1016/j.ygyno.2016.05.016
Collections
  • Clinical Studies
Subject
Humans
Leiomyosarcoma
Sarcoma
Uterine Neoplasms
Neoplasm Staging
Prognosis
Survival Rate
Adult
Middle Aged
Female
Randomized Controlled Trials as Topic
Research team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials
Language
eng
Date accepted
2016-05-15
License start date
2016-07
Citation
Gynecologic oncology, 2016, 142 (1), pp. 95 - 101

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.